Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;41(6):519-26.
doi: 10.1016/j.ctrv.2015.04.010. Epub 2015 Apr 29.

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma

Paola Queirolo  1 , Virginia Picasso  1 , Francesco Spagnolo  2
Affiliations
Review

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma

Paola Queirolo et al. Cancer Treat Rev. 2015 Jun.

Abstract

Combined BRAF and MEK inhibition out-performed BRAF inhibitor monotherapy in 3 randomized Phase 3 studies for BRAF-mutated metastatic melanoma patients and the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib is now an FDA-approved treatment in this setting. Nevertheless, the majority of patients face progressive disease even when treated with the combination. Mechanisms of resistance to BRAF inhibition have been extensively investigated, whilst less is known about the specific mechanisms of resistance to combined therapy. The aim of this paper is to review the efficacy and safety of the combination of BRAF plus MEK inhibitors compared with BRAF inhibitor monotherapy and immunotherapy, as well as to discuss the existing evidence for the mechanisms of resistance to combined therapy and assess future treatment strategies to improve outcome based on data provided by clinical and translational research studies.

Keywords: BRAF; Dabrafenib; MEK; Melanoma; Trametinib; Vemurafenib.

PubMed Disclaimer

MeSH terms